Text Size

One Hour Preoperative Gatifloxacin

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Christopher Ta, Stanford University
ClinicalTrials.gov Identifier:
NCT00350363
First received: July 5, 2006
Last updated: June 5, 2012
Last verified: June 2012
History of Changes
  Purpose

Comparison of 1 day versus 1 hour application of topical Zymar.


Condition Intervention Phase
Ophthalmic Surgery
 Drug: Zymar
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Prevention
Official Title: One Hour Preoperative Gatifloxacin

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • bacteria count [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
    bacteria count


Enrollment: 60
Study Start Date: January 2007
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Zymar
    zymar qid
    Other Name: gatifloxacin
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ophthalmic surgery

Exclusion Criteria:

  • taken antibiotics, allergic to fluoroquinolones
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00350363

Locations
United States, California
Stanford
Stanford, California, United States, 94304
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

No publications provided

Responsible Party: Christopher Ta, PI, Stanford University
ClinicalTrials.gov Identifier: NCT00350363     History of Changes
Other Study ID Numbers: 5004
Study First Received: July 5, 2006
Last Updated: June 5, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Gatifloxacin
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013